Aprea Therapeutics Files 8-K
Ticker: APRE · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
Related Tickers: APRE
TL;DR
APRE filed an 8-K, looks like routine stuff.
AI Summary
On February 5, 2025, Aprea Therapeutics, Inc. filed an 8-K report. The filing indicates no specific material events or financial updates were disclosed on this date, but rather serves as a routine filing or update.
Why It Matters
This filing indicates Aprea Therapeutics, Inc. is meeting its regulatory reporting obligations with the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Registrant
- February 5, 2025 (date) — Date of Report
- 0001558370-25-000641 (accession_number) — SEC Filing Accession Number
- 3805 Old Easton Road (address) — Principal Executive Offices
- Doylestown, PA (location) — Principal Executive Offices Location
- 18902 (zip_code) — Principal Executive Offices Zip Code
- 617-463-9385 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Aprea Therapeutics, Inc. on February 5, 2025?
The filing is a Current Report on Form 8-K, indicating that Aprea Therapeutics, Inc. is reporting information under Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Aprea Therapeutics, Inc.'s state of incorporation and IRS Employer Identification Number?
Aprea Therapeutics, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 84-2246769.
Where are Aprea Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.
What is the Commission File Number for Aprea Therapeutics, Inc.?
The Commission File Number for Aprea Therapeutics, Inc. is 001-39069.
Does this 8-K filing disclose any specific material events or financial statements?
The filing lists 'Other Events' and 'Financial Statements and Exhibits' as item information, but the provided text does not detail the specific content of these items, suggesting it may be a routine or placeholder filing.
Filing Stats: 433 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-02-05 08:30:18
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
Filing Documents
- apre-20250205x8k.htm (8-K) — 38KB
- apre-20250205xex99d1.htm (EX-99.1) — 13KB
- apre-20250205xex99d1002.jpg (GRAPHIC) — 9KB
- 0001558370-25-000641.txt ( ) — 190KB
- apre-20250205.xsd (EX-101.SCH) — 4KB
- apre-20250205_def.xml (EX-101.DEF) — 3KB
- apre-20250205_lab.xml (EX-101.LAB) — 16KB
- apre-20250205_pre.xml (EX-101.PRE) — 11KB
- apre-20250205x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On February 5, 2025, Aprea Therapeutics, Inc. issued a press release announcing an update to its existing patent portfolio. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release issued by Aprea Therapeutics, Inc. dated February 5, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: February 5, 2025 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer